New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
Provided By PR Newswire
Last update: Jun 12, 2025
Bleximenib, an investigational selective menin inhibitor, shows potential as combination therapy for the treatment of relapsed or refractory AML and newly diagnosed, intensive chemo-ineligible AML
Read more at prnewswire.com152.41
+0.4 (+0.26%)
Find more stocks in the Stock Screener
JNJ Latest News and Analysis
11 days ago - ChartmillJohnson & Johnson (NYSE:JNJ) - A Reliable Dividend Stock Worth ConsideringJohnson & Johnson (NYSE:JNJ) is a top dividend stock with a 3.32% yield, strong profitability, and a reliable payout history, making it a solid choice for income investors.
